Clinical Trial Update: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating a personalized neoantigen dose-adjusted vaccine in combination with pembrolizumab for squamous cell cancers of the lung and head and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Personalized neoantigen vaccine (investigational)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer | Phase 1 | Status: SUSPENDED